Jazz Pharmaceuticals' ZIIHERA Receives Regulatory Approvals for Biliary Tract Cancer

Jazz Pharmaceuticals and its partners received U.S. accelerated approval and EU conditional marketing authorization for ZIIHERA (zanidatamab-hrii) for eligible patients with biliary tract cancer. The drug is licensed from Zymeworks. Jazz is also conducting the Phase 3 HERIZON-GEA-01 trial, testing ZIIHERA with chemotherapy as a first-line treatment for advanced or metastatic HER2-positive gastroesophageal adenocarcinoma. The article reports no financial results or stock-price impact.